The Utility of DHL-HisZnNa, a Novel Antioxidant, Against Anticancer Agent-Induced Alopecia in Breast Cancer Patients: A Multicenter Phase II Clinical Trial
February 2019
in “
Breast Cancer Research and Treatment
”
TLDR DHL-HisZnNa may help reduce hair loss from chemotherapy, but more research is needed.
The study evaluated the effectiveness of DHL-HisZnNa, a novel antioxidant, in preventing chemotherapy-induced alopecia in breast cancer patients through a multicenter phase II clinical trial in Japan involving 103 patients. Despite all 101 patients analyzed for safety experiencing grade 2 alopecia, the treatment might have aided in recovery, with a median alopecia duration of 119 days for four chemotherapy courses and 203 days for eight courses. Mild to moderate adverse events occurred in 11 patients, and 53 reported alopecia-related symptoms. While DHL-HisZnNa showed potential in reducing CIA, further studies were needed to confirm its efficacy and safety.
